ArticleRSC medicinal chemistry2026
Novel hydroxytyrosol esters as potential anti-amyloid and neuroprotective agents for Alzheimer's disease.
Article in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hydroxytyrosol as a Multitarget Neuroprotective Agent: Molecular Mechanisms, Pharmacokinetics and Therapeutic Potential in Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is associated with the aggregation of β-amyloid (Aβ) peptides and oxidative stress, two interconnected processes that contribute to neuronal dysfunction and cognitive decline. Natural polyphenols such as oleuropein and its metabolite hydroxytyrosol display antioxidant and anti-amyloidogenic properties, but oleuropein suffers from limited stability due to glycosidic hydrolysis. To develop more robust and potent oleuropein analogs, we synthesized a series of hydroxytyrosol-based esters in which the secoiridoid glucoside scaffold of oleuropein was replaced by lipophilic substituents designed to enhance molecular stability and interactions with Aβ peptide. The compounds were evaluated for their ability to interact with Aβ40 using ESI-MS, circular dichroism (CD), and thioflavin-T fluorescence (ThT), along with complementary antioxidant assays. Most of the compounds formed stable non-covalent complexes with Aβ40, inhibited early aggregation events, and prevented the peptide's conformational transition from random coil to β-sheet. To assess biological efficacy and safety
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.